115 related articles for article (PubMed ID: 27569395)
1. Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells.
Xie S; Jiang H; Zhai XW; Wei F; Wang SD; Ding J; Chen Y
Acta Pharmacol Sin; 2016 Nov; 37(11):1481-1489. PubMed ID: 27569395
[TBL] [Abstract][Full Text] [Related]
2. Venetoclax and pegcrisantaspase for complex karyotype acute myeloid leukemia.
Emadi A; Kapadia B; Bollino D; Bhandary B; Baer MR; Niyongere S; Strovel ET; Kaizer H; Chang E; Choi EY; Ma X; Tighe KM; Carter-Cooper B; Moses BS; Civin CI; Mahurkar A; Shetty AC; Gartenhaus RB; Kamangar F; Lapidus RG
Leukemia; 2021 Jul; 35(7):1907-1924. PubMed ID: 33199836
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.
Chen R; Wierda WG; Chubb S; Hawtin RE; Fox JA; Keating MJ; Gandhi V; Plunkett W
Blood; 2009 May; 113(19):4637-45. PubMed ID: 19234140
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional CDK inhibitors, CYC065 and THZ1 promote Bim-dependent apoptosis in primary and recurrent GBM through cell cycle arrest and Mcl-1 downregulation.
Juric V; Hudson L; Fay J; Richards CE; Jahns H; Verreault M; Bielle F; Idbaih A; Lamfers MLM; Hopkins AM; Rehm M; Murphy BM
Cell Death Dis; 2021 Aug; 12(8):763. PubMed ID: 34344865
[TBL] [Abstract][Full Text] [Related]
5. Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia.
Zhang L; Cai T; Lin X; Huang X; Bui MH; Plotnik JP; Bellin RJ; Faivre EJ; Kuruvilla VM; Lam LT; Lu X; Zha Z; Feng W; Hessler P; Uziel T; Zhang Q; Cavazos A; Han L; Ferguson DC; Mehta G; Shanmugavelandy SS; Magoc TJ; Rowe J; Goodwin NC; Dorritie KA; Boyiadzis M; Albert DH; McDaniel KF; Kati WM; Konopleva M; Shen Y
Mol Cancer Ther; 2021 Oct; 20(10):1809-1819. PubMed ID: 34253595
[TBL] [Abstract][Full Text] [Related]
6. The effects of STA-9090 (Ganetespib) and venetoclax (ABT-199) combination on apoptotic pathways in human cervical cancer cells.
Karademir D; Özgür A
Med Oncol; 2023 Jul; 40(8):234. PubMed ID: 37432531
[TBL] [Abstract][Full Text] [Related]
7. Dihydroartemisinin Enhances the Therapeutic Efficacy of BH3 Mimetic Inhibitor in Acute Lymphoblastic Leukemia Cells via Inhibition of Mcl-1.
Nazmabadi R; Pooladi M; Amri J; Abbasi Y; Karami H; Darvish M
Asian Pac J Cancer Prev; 2024 Jan; 25(1):325-332. PubMed ID: 38285800
[TBL] [Abstract][Full Text] [Related]
8. [Curcumin Combined with Thalidomide Inhibits Proliferation of KG-1 Cells and Its Related Mechanisms].
Liu J; Huang Y; Liu Z
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):422-427. PubMed ID: 38660846
[TBL] [Abstract][Full Text] [Related]
9. Imidazo[1,2-
Szebeni GJ; Balog JA; Demjén A; Alföldi R; Végi VL; Fehér LZ; Mán I; Kotogány E; Gubán B; Batár P; Hackler L; Kanizsai I; Puskás LG
Molecules; 2018 Nov; 23(11):. PubMed ID: 30388846
[TBL] [Abstract][Full Text] [Related]
10. An Anti-CD7 Antibody-Drug Conjugate Target Showing Potent Antitumor Activity for T-Lymphoblastic Leukemia (T-ALL).
Wang S; Zhang R; Zhong K; Guo W; Tong A
Biomolecules; 2024 Jan; 14(1):. PubMed ID: 38254706
[TBL] [Abstract][Full Text] [Related]
11. Synthetic 1,2,4-triazole-3-carboxamides Induce Cell Cycle Arrest and Apoptosis in Leukemia Cells.
Ekaterina Z; Daria S; Lyubov G; Ekaterina M; Varvara M; Diana G; Andrey M; Ekaterina L
Curr Pharm Des; 2023; 29(43):3478-3487. PubMed ID: 38083885
[TBL] [Abstract][Full Text] [Related]
12. The Effects of ABT-199 and Dihydroartemisinin Combination on Cell Growth and Apoptosis in Human U937 and KG-1 Cancer Cells.
Nazmabadi R; Pooladi M; Amri J; Darvish M; Abbasi Y; Karami H
Asian Pac J Cancer Prev; 2024 Jan; 25(1):343-350. PubMed ID: 38285802
[TBL] [Abstract][Full Text] [Related]
13. MC180295 is a highly potent and selective CDK9 inhibitor with preclinical in vitro and in vivo efficacy in cancer.
Zhang H; Huang C; Gordon J; Yu S; Morton G; Childers W; Abou-Gharbia M; Zhang Y; Jelinek J; Issa JJ
Clin Epigenetics; 2024 Jan; 16(1):3. PubMed ID: 38172923
[TBL] [Abstract][Full Text] [Related]
14. The orally bioavailable GSPT1/2 degrader SJ6986 exhibits in vivo efficacy in acute lymphoblastic leukemia.
Chang Y; Keramatnia F; Ghate PS; Nishiguchi G; Gao Q; Iacobucci I; Yang L; Chepyala D; Mishra A; High AA; Goto H; Akahane K; Peng J; Yang JJ; Fischer M; Rankovic Z; Mullighan CG
Blood; 2023 Aug; 142(7):629-642. PubMed ID: 37172201
[TBL] [Abstract][Full Text] [Related]
15. Microfluidic chemical cytometry of peptide degradation in single drug-treated acute myeloid leukemia cells.
Kovarik ML; Shah PK; Armistead PM; Allbritton NL
Anal Chem; 2013 May; 85(10):4991-7. PubMed ID: 23590517
[TBL] [Abstract][Full Text] [Related]
16. Stereospecific Cross-Coupling Reactions Provide Conformationally-Biased Arylalkanes with Anti-Leukemia Activity.
Sanford AB; Tollefson EJ; Jarvo ER
Isr J Chem; 2020 Mar; 60():402-405. PubMed ID: 33442068
[TBL] [Abstract][Full Text] [Related]
17. Targeting CDK9: a promising therapeutic opportunity in prostate cancer.
Rahaman MH; Kumarasiri M; Mekonnen LB; Yu M; Diab S; Albrecht H; Milne RW; Wang S
Endocr Relat Cancer; 2016 Dec; 23(12):T211-T226. PubMed ID: 27582311
[TBL] [Abstract][Full Text] [Related]
18. BCL2 Inhibition by Venetoclax: Targeting the Achilles' Heel of the Acute Myeloid Leukemia Stem Cell?
Pullarkat VA; Newman EM
Cancer Discov; 2016 Oct; 6(10):1082-1083. PubMed ID: 27698099
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies.
Bui MH; Lin X; Albert DH; Li L; Lam LT; Faivre EJ; Warder SE; Huang X; Wilcox D; Donawho CK; Sheppard GS; Wang L; Fidanze S; Pratt JK; Liu D; Hasvold L; Uziel T; Lu X; Kohlhapp F; Fang G; Elmore SW; Rosenberg SH; McDaniel KF; Kati WM; Shen Y
Cancer Res; 2017 Jun; 77(11):2976-2989. PubMed ID: 28416490
[TBL] [Abstract][Full Text] [Related]
20. CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia.
Rahaman MH; Yu Y; Zhong L; Adams J; Lam F; Li P; Noll B; Milne R; Peng J; Wang S
Invest New Drugs; 2019 Aug; 37(4):625-635. PubMed ID: 30194564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
